4-[3-(benzyloxy)phenyl]-6-chloropyrimidine | 1073485-23-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-[3-(benzyloxy)phenyl]-6-chloropyrimidine
• 英文别名: 4-chloro-6-(3-benzyloxyphenyl)-pyrimidine；4-Chloro-6-(3-phenylmethoxyphenyl)pyrimidine
• CAS: 1073485-23-0
• 化学式: C₁₇H₁₃ClN₂O
• 分子量: 296.756
• InChiKey: CXKIINZQWRQZCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[3-(benzyloxy)phenyl]-6-chloropyrimidine 、 ethyl (3-aminobenzyl)propylphosphinate 在 盐酸 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 异丙醇 为溶剂， 以20%的产率得到ethyl [3-({6-[3-(benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinate
  参考文献：
  名称：

  Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors

  摘要：

  Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.

  DOI：

  10.1021/jm401742r
• 作为产物：
  描述：

  4,6-二氯嘧啶 、 3-苄氧基苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 21.5h， 以80%的产率得到4-[3-(benzyloxy)phenyl]-6-chloropyrimidine
  参考文献：
  名称：

  Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors

  摘要：

  Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.

  DOI：

  10.1021/jm401742r

文献信息

• 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
  申请人：Wabnitz Philipp

  公开号：US20110306602A1

  公开（公告）日：2011-12-15

  The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

  本发明涉及一般公式(I)的细胞周期依赖性激酶抑制剂及其治疗应用。此外，本发明还涉及用于预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、传染性疾病、心血管疾病和神经退行性疾病的化合物。
• 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
  申请人：Ingenium Pharmaceuticals GmbH

  公开号：US20130338147A1

  公开（公告）日：2013-12-19

  The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

  本发明涉及抑制细胞周期依赖性激酶及其治疗应用的药物。此外，本发明涉及通过给予至少一种细胞周期依赖性激酶抑制剂的有效剂量来预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、传染性疾病、心血管疾病和神经退行性疾病的方法。
• US8507498B2
  申请人：——

  公开号：US8507498B2

  公开（公告）日：2013-08-13
• [EN] 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES<br/>[FR] INHIBITEURS DE PROTÉINE KINASES
  申请人：INGENIUM PHARMACEUTICALS GMBH

  公开号：WO2008129080A1

  公开（公告）日：2008-10-30

  [EN] The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
  [FR] La présente invention porte sur des inhibiteurs de kinases dépendantes de cyclines et sur leurs applications thérapeutiques. De plus, l'invention porte sur des procédés pour prévenir et/ou traiter n'importe quel type de douleur, troubles inflammatoires, maladies immunologiques, maladies prolifératives, maladies infectieuses, maladies cardiovasculaires et maladies neurodégénératives, comprenant l'administration d'une quantité efficace d'au moins un inhibiteur de kinases dépendantes de cyclines.
• Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors
  作者：Gábor Németh、Zoltán Greff、Anna Sipos、Zoltán Varga、Rita Székely、Mónika Sebestyén、Zsuzsa Jászay、Szabolcs Béni、Zoltán Nemes、Jean-Luc Pirat、Jean-Noël Volle、David Virieux、Ágnes Gyuris、Katalin Kelemenics、Éva Áy、Janos Minarovits、Susan Szathmary、György Kéri、László Őrfi

  DOI：10.1021/jm401742r

  日期：2014.5.22

  Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.